JP Morgan Chase’s Ascendis Pharma A/S ASND Stock Holding History

JP Morgan Chase’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,000	Closed	-$7.64M	–	7725
2026 Q1	$7.64M	Hold	35,000	–	–	﹤0.01%	2932
2025 Q4	$7.46M	Sell	35,000 -40,100	-53%	-$8.28M	﹤0.01%	2962
2025 Q3	$14.9M	Buy	+75,100	New	+$14M	﹤0.01%	2345
2023 Q4	–	Sell	-25,000	Closed	-$2.34M	–	7504
2023 Q3	$2.34M	Sell	25,000 -75,000	-75%	-$7.02M	﹤0.01%	3440
2023 Q2	$8.93M	Buy	100,000 +25,000	+33%	+$2.18M	﹤0.01%	2383
2023 Q1	$8.04M	Buy	+75,000	New	+$8.58M	﹤0.01%	2469
2022 Q2	–	Sell	-3,000	Closed	-$352K	–	6445
2022 Q1	$352K	Buy	+3,000	New	+$347K	﹤0.01%	4898
2021 Q1	–	Sell	-27,000	Closed	-$4.5M	–	6051
2020 Q4	$4.5M	Buy	+27,000	New	+$4.46M	﹤0.01%	2898
2020 Q1	–	Sell	-36,000	Closed	-$5.01M	–	5278
2019 Q4	$5.01M	Buy	+36,000	New	+$4M	﹤0.01%	2674

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

JP Morgan Chase's ASND Position: Q2 2026 in Review

JP Morgan Chase reduced its Ascendis Pharma A/S (ASND) stake by 32% in Q2 2026, selling an estimated $40.1M and leaving 367,781 shares worth $97M. The position accounts for 0.01% of the portfolio, ranked #1091.

JP Morgan Chase first reported a position in ASND in Q3 2017 and has held it in 33 quarters since. The position peaked at $118M in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

JP Morgan Chase held 367,781 shares of Ascendis Pharma A/S worth $97M as of Q2 2026.
JP Morgan Chase sold 171,653 Ascendis Pharma A/S shares in Q2 2026, an estimated $40.1M.
Ascendis Pharma A/S made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1091 holding.
JP Morgan Chase first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 33 quarters since.
JP Morgan Chase's Ascendis Pharma A/S position peaked at $118M in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.